598 related articles for article (PubMed ID: 11479220)
1. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells.
Dervieux T; Blanco JG; Krynetski EY; Vanin EF; Roussel MF; Relling MV
Cancer Res; 2001 Aug; 61(15):5810-6. PubMed ID: 11479220
[TBL] [Abstract][Full Text] [Related]
2. Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase.
Krynetski EY; Krynetskaia NF; Yanishevski Y; Evans WE
Mol Pharmacol; 1995 Jun; 47(6):1141-7. PubMed ID: 7603453
[TBL] [Abstract][Full Text] [Related]
3. Differential role of thiopurine methyltransferase in the cytotoxic effects of 6-mercaptopurine and 6-thioguanine on human leukemia cells.
Karim H; Ghalali A; Lafolie P; Vitols S; Fotoohi AK
Biochem Biophys Res Commun; 2013 Jul; 437(2):280-6. PubMed ID: 23811272
[TBL] [Abstract][Full Text] [Related]
4. S-adenosylmethionine regulates thiopurine methyltransferase activity and decreases 6-mercaptopurine cytotoxicity in MOLT lymphoblasts.
Milek M; Karas Kuzelicki N; Smid A; Mlinaric-Rascan I
Biochem Pharmacol; 2009 Jun; 77(12):1845-53. PubMed ID: 19428339
[TBL] [Abstract][Full Text] [Related]
5. The effect of thiopurine drugs on DNA methylation in relation to TPMT expression.
Hogarth LA; Redfern CP; Teodoridis JM; Hall AG; Anderson H; Case MC; Coulthard SA
Biochem Pharmacol; 2008 Oct; 76(8):1024-35. PubMed ID: 18708030
[TBL] [Abstract][Full Text] [Related]
6. Establishment of thiopurine S-methyltransferase gene knockdown in jurkat T-lymphocytes: an in vitro model of TPMT polymorphism.
Misdaq M; Andag R; Oellerich M; Asif AR; von Ahsen N
Ther Drug Monit; 2012 Oct; 34(5):584-92. PubMed ID: 22972540
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics.
Hartford C; Vasquez E; Schwab M; Edick MJ; Rehg JE; Grosveld G; Pui CH; Evans WE; Relling MV
Cancer Res; 2007 May; 67(10):4965-72. PubMed ID: 17510427
[TBL] [Abstract][Full Text] [Related]
8. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
[TBL] [Abstract][Full Text] [Related]
9. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.
Relling MV; Hancock ML; Rivera GK; Sandlund JT; Ribeiro RC; Krynetski EY; Pui CH; Evans WE
J Natl Cancer Inst; 1999 Dec; 91(23):2001-8. PubMed ID: 10580024
[TBL] [Abstract][Full Text] [Related]
10. The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia.
Lennard L; Richards S; Cartwright CS; Mitchell C; Lilleyman JS; Vora A;
Clin Pharmacol Ther; 2006 Oct; 80(4):375-83. PubMed ID: 17015055
[TBL] [Abstract][Full Text] [Related]
11. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold.
Gardiner SJ; Gearry RB; Begg EJ; Zhang M; Barclay ML
Clin Gastroenterol Hepatol; 2008 Jun; 6(6):654-60; quiz 604. PubMed ID: 18467186
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients.
Gilissen LP; Bierau J; Derijks LJ; Bos LP; Hooymans PM; van Gennip A; Stockbrügger RW; Engels LG
Aliment Pharmacol Ther; 2005 Oct; 22(7):605-11. PubMed ID: 16181300
[TBL] [Abstract][Full Text] [Related]
13. DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma.
Hedeland RL; Hvidt K; Nersting J; Rosthøj S; Dalhoff K; Lausen B; Schmiegelow K
Cancer Chemother Pharmacol; 2010 Aug; 66(3):485-91. PubMed ID: 19956952
[TBL] [Abstract][Full Text] [Related]
14. The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs.
Coulthard SA; Hogarth LA; Little M; Matheson EC; Redfern CP; Minto L; Hall AG
Mol Pharmacol; 2002 Jul; 62(1):102-9. PubMed ID: 12065760
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms underlying the enhanced sensitivity of thiopurine-resistant T-lymphoblastic cell lines to methyl mercaptopurineriboside.
Fotoohi AK; Wrabel A; Moshfegh A; Peterson C; Albertioni F
Biochem Pharmacol; 2006 Sep; 72(7):816-23. PubMed ID: 16859645
[TBL] [Abstract][Full Text] [Related]
16. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
Gearry RB; Barclay ML
J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
[TBL] [Abstract][Full Text] [Related]
17. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K; Forestier E; Kristinsson J; Söderhäll S; Vettenranta K; Weinshilboum R; Wesenberg F;
Leukemia; 2009 Mar; 23(3):557-64. PubMed ID: 18987654
[TBL] [Abstract][Full Text] [Related]
18. Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia?
Fakhoury M; Andreu-Gallien J; Mahr A; Medard Y; Azougagh S; Vilmer E; Jacqz-Aigrain E
J Clin Pharm Ther; 2007 Dec; 32(6):633-9. PubMed ID: 18021342
[TBL] [Abstract][Full Text] [Related]
19. The clinical impact of thiopurine methyltransferase polymorphisms on thiopurine treatment.
Coulthard SA; Matheson EC; Hall AG; Hogarth LA
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1385-91. PubMed ID: 15571264
[TBL] [Abstract][Full Text] [Related]
20. Impaired transport as a mechanism of resistance to thiopurines in human T-lymphoblastic leukemia cells.
Fotoohi AK; Lindqvist M; Peterson C; Albertioni F
Nucleosides Nucleotides Nucleic Acids; 2006; 25(9-11):1039-44. PubMed ID: 17065061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
